Domingo J L
Laboratory of Toxicology and Biochemistry, School of Medicine, University of Barcelona, Reus, Spain.
J Toxicol Clin Toxicol. 1989;27(6):355-67. doi: 10.3109/15563658909000356.
Desferrioxamine (DFO), traditionally used as an iron chelator has been shown to increase urinary aluminum output in humans and aluminum-loaded mice, rats and rabbits. However, major side-effects of DFO treatment have been observed and the drug may accumulate in dialysis patients receiving repeated doses. In recent years, it has been reported that some dicarboxylic or tricarboxylic acids such as succinic, malic or citric may be considered as possible alternatives to DFO in the management of aluminum accumulation. Ethylene-di-(o-hydroxyphenylacetic acid)-like compounds may also have potential as alternatives to DFO in the treatment of aluminum accumulation and aluminum-induced toxicity. Investigation of new therapeutic agents with lower toxicity than DFO and clinical advantages in administration and cost is clearly encouraged.
去铁胺（DFO）传统上用作铁螯合剂，已被证明可增加人体以及铝负荷的小鼠、大鼠和兔子的尿铝排出量。然而，已观察到DFO治疗存在主要副作用，且该药物可能在接受重复给药的透析患者体内蓄积。近年来，有报道称一些二羧酸或三羧酸，如琥珀酸、苹果酸或柠檬酸，在铝蓄积的管理中可被视为DFO的可能替代物。乙二 -（邻羟基苯乙酸）类化合物在治疗铝蓄积和铝诱导的毒性方面也可能具有作为DFO替代物的潜力。显然鼓励研究毒性低于DFO且在给药和成本方面具有临床优势的新型治疗药物。
